Federal grants to Integral Molecular Inc
Integral Molecular Inc in Philadelphia, Pennsylvania received $8.7 million in federal grants from fiscal 2021 to 2025, across 10 awards. Its largest program was Biomedical Research and Research Training, with $5.0 million. In fiscal 2025 it was awarded $2.6 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$8.7 million
- Awards10
- Awarded in FY 2025$2.6 million
- Largest award$1.8 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 3 | $1.6 million |
| FY 2022 | 4 | $1.8 million |
| FY 2023 | 3 | $1.1 million |
| FY 2024 | 3 | $1.6 million |
| FY 2025 | 4 | $2.6 million |
Programs that fund Integral Molecular Inc
| Program | Awards | Amount |
|---|---|---|
| Biomedical Research and Research Training | 5 | $5.0 million |
| Cancer Treatment Research | 1 | $1.7 million |
| Allergy and Infectious Diseases Research | 2 | $1.1 million |
| Drug Use and Addiction Research Programs | 1 | $474,833 |
| Aging Research | 1 | $447,566 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 10 | $8.7 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Specificity screening drug development tool for biotherapeutic safety - abstract off-target safety problems are the single leading cause of preclinical drug failures. As a result, specificity profiling has become an fda requirement for monoclonal antibodies (MABS) as well as other emerging biotherap | Biomedical Research and Research Training | September 5, 2024 | $1.8 million |
| Development of claudin mabs for treating solid tumors - abstract solid tumors lead to 580,000 deaths annually in the us, and safe and effective therapeutics for many late- stage solid tumors are lacking. Ovarian cancer alone kills 14,000 people each year, and many patients do not respond to currentl | Cancer Treatment Research | May 31, 2022 | $1.7 million |
| Development of KV1.3 monoclonal antibodies targeting tem cells for treating autoimmune disorders | Biomedical Research and Research Training | March 17, 2021 | $1.2 million |
| High-throughput discovery of antibodies against understudied membrane proteins using mrna - abstract of the 20,000 genes in the human genome, approximately 4,000 are considered “druggable”. However, less than 10% of these druggable proteins are actually targeted by fda-approved drugs. In 2014, the i | Biomedical Research and Research Training | August 15, 2025 | $923,143 |
| High-throughput identification of membrane protein mabs | Biomedical Research and Research Training | June 25, 2021 | $706,380 |
| Development of safe and rapid reporter viruses for studying pathogenic and pandemic viruses - abstract neutralizing titer is a demonstrated correlate of protection across most viral pathogens. The traditional assay to assess neutralization titer is the plaque reduction neutralization test (PRNT), wh | Allergy and Infectious Diseases Research | June 25, 2024 | $577,030 |
| Generation of pan-reactive antibody and cytokine reagents for immunologic analysis of bats - abstract understanding the immune response in bats can aid in the response to viral outbreaks and other diseases, but the bat research community suffers from a scarcity of immunologic research reagents. The | Allergy and Infectious Diseases Research | August 19, 2025 | $495,061 |
| Development of NAV1.7 monoclonal antibodies for treating pain - abstract chronic pain is a significant medical problem, affecting over 50 million americans and representing the largest cause of disability and disease burden globally. Current pain relief treatments rely heavily on opioid drugs, which | Drug Use and Addiction Research Programs | September 17, 2021 | $474,833 |
| Identifying regulators of cellular aging that can prevent alzheimer's disease - abstract aging is the leading risk factor for alzheimer’s disease (AD) and many other chronic diseases, with more than 6.5 million cases of ad in the us. Regulating or slowing cellular aging, particularly in microglia an | Aging Research | May 18, 2022 | $447,566 |
| High-throughput discovery of antibodies against understudied membrane proteins - abstract of the 20,000 genes in the human genome, approximately 4,000 are considered “druggable” by pharmaceuticals. However, less than 10% of these druggable proteins are actually targeted by fda-approved drugs. In 201 | Biomedical Research and Research Training | April 20, 2023 | $295,924 |
Questions people ask
How much federal grant money does Integral Molecular Inc get?
$8.7 million in 10 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Integral Molecular Inc the most?
The Department of Health and Human Services, with $8.7 million in 10 awards.
What is Integral Molecular Inc's largest federal grant?
$1.8 million under Biomedical Research and Research Training, with its first action in the period on September 5, 2024. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Integral Molecular Inc?
Its largest are Biomedical Research and Research Training, Cancer Treatment Research and Allergy and Infectious Diseases Research.
Other grant recipients in Philadelphia
- The Trustees of the University of Pennsylvania
- Southeastern Pennsylvania Transportation Authority
- Opportunity Finance Network
- Pennvest
- Philadelphia Housing Authority
- The Children's Hospital of Philadelphia
- Temple University-of the Commonwealth System of Higher Education
- City of Philadelphia
Largest federal grant recipients in Pennsylvania · Federal grants in Pennsylvania